Stock SYNT SYNTHETICMR AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials SyntheticMR AB

Equities

SYNT

SE0015987946

Advanced Medical Equipment & Technology

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 06:00:00 2024-01-30 pm EST 		5-day change 1st Jan Change
27.7 SEK +1.09% Intraday chart for SyntheticMR AB -.--% +4.14%
Apr. 17 SyntheticMR AB and SimonMed Imaging Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from Synthetic Software at SimonMed Facilities CI
Mar. 27 SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 900.9 1,382 2,505 1,416 1,108 1,155 - -
Enterprise Value (EV) 1 866.2 1,369 2,493 1,376 1,087 1,126 1,110 1,080
P/E ratio 237 x 3,109 x 310 x 227 x 116 x 50.5 x 29.2 x 21.1 x
Yield 0.67% - - - - 0.72% 1.08% 1.44%
Capitalization / Revenue 19.7 x 28.4 x 42.9 x 20.7 x 12.4 x 10.3 x 7.96 x 6.37 x
EV / Revenue 18.9 x 28.1 x 42.7 x 20.1 x 12.2 x 10.1 x 7.65 x 5.95 x
EV / EBITDA 104 x 280 x 171 x 111 x 53.5 x 32.1 x 19.5 x 14.1 x
EV / FCF 94.7 x - 589 x -53.4 x -65.1 x 141 x 39.1 x 23 x
FCF Yield 1.06% - 0.17% -1.87% -1.53% 0.71% 2.56% 4.35%
Price to Book 20.6 x - 54.4 x 13.2 x 9.5 x 8.21 x 6.88 x 5.6 x
Nbr of stocks (in thousands) 40,401 40,401 40,401 41,651 41,651 41,688 - -
Reference price 2 22.30 34.20 62.00 34.00 26.60 27.70 27.70 27.70
Announcement Date 2/27/20 2/18/21 2/22/22 2/15/23 2/20/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 45.8 48.73 58.42 68.27 89.21 112 145.1 181.4
EBITDA 1 8.329 4.885 14.59 12.4 20.32 35.05 57.02 76.73
EBIT 1 4.917 0.865 9.988 7.223 14.08 28.25 49.12 67.9
Operating Margin 10.74% 1.78% 17.1% 10.58% 15.78% 25.23% 33.86% 37.43%
Earnings before Tax (EBT) 1 4.901 0.816 10.42 7.912 13.08 28.76 49.69 68.79
Net income 1 3.729 0.663 7.9 5.879 10.01 22.84 39.45 54.62
Net margin 8.14% 1.36% 13.52% 8.61% 11.22% 20.4% 27.2% 30.11%
EPS 2 0.0940 0.0110 0.2000 0.1500 0.2300 0.5483 0.9473 1.311
Free Cash Flow 1 9.144 - 4.236 -25.74 -16.68 8 28.4 47
FCF margin 19.96% - 7.25% -37.7% -18.7% 7.15% 19.58% 25.91%
FCF Conversion (EBITDA) 109.79% - 29.03% - - 22.82% 49.81% 61.25%
FCF Conversion (Net income) 245.21% - 53.62% - - 35.03% 71.98% 86.05%
Dividend per Share 2 0.1500 - - - - 0.2000 0.3000 0.4000
Announcement Date 2/27/20 2/18/21 2/22/22 2/15/23 2/20/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 13.6 18.37 9.875 18.72 19.03 20.64 16.14 21.24 21.71 30.12 24.89 26.43 28.41 32.23
EBITDA 1 3.348 6.413 -2.41 5.626 5.713 3.468 -0.54 4.321 6.115 10.42 6.179 7.543 9.014 12.32
EBIT 1 2.191 5.225 -3.621 4.371 4.393 2.079 -2.022 2.804 4.519 8.775 4.479 5.843 7.314 10.62
Operating Margin 16.11% 28.45% -36.67% 23.35% 23.08% 10.07% -12.53% 13.2% 20.82% 29.13% 17.99% 22.11% 25.74% 32.95%
Earnings before Tax (EBT) 1 2.351 5.397 -3.45 5.186 5.311 0.865 -2.229 4.03 4.536 6.744 4.585 5.974 7.447 10.75
Net income 1 2.309 3.113 -3.452 5.112 4.093 0.527 -2.229 3.575 4.085 4.582 3.641 4.743 5.913 8.539
Net margin 16.98% 16.95% -34.96% 27.3% 21.5% 2.55% -13.81% 16.83% 18.82% 15.21% 14.63% 17.95% 20.81% 26.49%
EPS 2 0.0600 0.0800 -0.0800 0.1300 0.1100 0.0100 -0.0500 0.0900 0.1000 0.1000 0.0874 0.1139 0.1420 0.2050
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/11/21 2/22/22 5/10/22 8/23/22 11/16/22 2/15/23 5/23/23 8/22/23 11/10/23 2/20/24 - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 34.7 13 11.6 40.5 21.3 28.4 44.3 74.7
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 9.14 - 4.24 -25.7 -16.7 8 28.4 47
ROE (net income / shareholders' equity) 8% - 19% 7% 6% 17.8% 25.8% 29.5%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 1.080 - 1.140 2.570 2.800 3.370 4.030 4.940
Cash Flow per Share 0.3200 - - - - - - -
Capex 1 3.62 - 5.11 10.5 9.72 9.6 10.9 13.6
Capex / Sales 7.91% - 8.74% 15.37% 10.89% 8.57% 7.51% 7.5%
Announcement Date 2/27/20 2/18/21 2/22/22 2/15/23 2/20/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for SyntheticMR AB

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
27.7 SEK
Average target price
30 SEK
Spread / Average Target
+8.30%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

1st Jan change Capi.
SYNTHETICMR AB Stock SyntheticMR AB
+4.14% 105M
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+4.36% 32.47B
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+14.14% 7.45B
SECTRA AB Stock Sectra AB
+22.93% 3.89B
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-16.29% 3.15B
OMNICELL, INC. Stock Omnicell, Inc.
-25.96% 1.28B
LUNIT INC. Stock Lunit Inc.
-36.14% 1.09B
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
-0.13% 893M
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-35.42% 902M
VERADIGM INC. Stock Veradigm Inc.
-24.12% 857M
Medical Software & Technology Services
  1. Stock Market
  2. Equities
  3. SYNT Stock
  4. Financials SyntheticMR AB